Edgewise Therapeutics (EWTX) Interest Expenses (2020 - 2025)

Edgewise Therapeutics (EWTX) has 6 years of Interest Expenses data on file, last reported at $255.7 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses fell 4.36% year-over-year to $255.7 million; the trailing twelve-month figure through Dec 2025 stood at $255.7 million (down 4.36% YoY), and the FY2025 full-year result was $255.7 million, down 4.36% from the prior year.
• Interest Expenses declined to $255.7 million in Q4 2025, from $267.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $267.4 million in Q4 2024 to a low of $53000.0 in Q4 2023.
• A 5-year average of $44.0 million and a median of $3.3 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 97.9% in 2022 and soared 504422.64% in 2024, its largest moves.
• Tracing EWTX's Interest Expenses over 5 years: stood at $20.5 million in 2021, then sank by 97.9% to $432000.0 in 2022, then plunged by 87.73% to $53000.0 in 2023, then soared by 504422.64% to $267.4 million in 2024, then dropped by 4.36% to $255.7 million in 2025.
• Business Quant data shows EWTX's Interest Expenses at $255.7 million in Q4 2025, $267.4 million in Q4 2024, and $1.1 million in Q2 2024.